Across multiple cancer types, predicted neo-antigen burden, but not overall mutational load, correlated with patient survival and CD8A and PD-1 expression [11], as well as immune cytolytic activity (GZMA and PRF1 expression) [12]. The gene discussed is PDCD1; the disease is cancer.